Quote:

---

Industry and regulatory pressures will force smaller inefficient compound pharmacies to sell, merge or invest ( Q2 & Q3 10Qs have demonstrated SCRC/MAP is not a small inefficient compound pharmacy).

---

Spot on Guts, Scrc is not an inefficient compound company. Its a small company getting ready to expand into a very lucrative industry as detailed in my research of its industry for M&A , as stated above we can merge or invest into staying in the industry. Either way with the expansion and continued revenue growth, this is a position to be holding.

There's been talk about what the benefits of even a reverse split would bring on another board. I for one support a reverse split that would move us out of penny land and all this volatility and reduce the O/S. So much open for discussion now that we are looking at very good potential for back to back EPS